dr. rudin on caveats of the keynote-021 in patients with nsclc
Published 6 years ago • 121 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
1:41
dr. rudin on rova-t in patients with small cell lung cancer
-
1:01
dr. rudin on immunotherapy biomarkers in lung cancer
-
1:36
dr. rudin on expansion of immunotherapy in lung cancer
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
1:11
dr charles rudin: changing the tide in funding for lung cancer research
-
1:29
dr. charles rudin: changing the tide in lung cancer research funding
-
1:29
dr. vanderwalde on the clinical implications of impower150 and keynote-021
-
8:46
today immunotherapy can cure even fourth stage cancer: dr dattatreyudu nori
-
2:02
the faces of mitochondrial disease
-
4:23
the ras-raf pathway: new cancer research
-
9:40
priority review designation in nsclc and 2018 gu symposium highlights
-
0:53
charles rudin, md, phd, discusses the keynote-604 study and the role of keytruda in es-sclc
-
1:17
dr. kris on the challenges of treating lung cancer
-
4:43
first in-human trials of rovalpituzumab for sclc
-
1:28
dr. kris on sequencing challenges in lung cancer
-
4:21
targeting the raf pathway in lung cancer
-
1:36
dr. drilon on ntrk rearrangement in lung cancer
-
5:03
immunotherapy in metastatic nsclc
-
1:53
dr. kris on the crizotinib clinical trials
-
1:33
dr. abou-alfa on trials investigating immunotherapy in hcc
-
12:22
bridging therapy with tenecteplase or alteplase in patients with large ischemic core